Gut microbiota dysbiosis and increased plasma trimethylamine N-oxide in patients with chronic kidney disease
Authors:
Preprint
- 6 April 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Background The gut microbiota has been identified as a source of pathogenic mediators in chronic kidney disease (CKD). A gut microbiota-dependent metabolite, trimethylamine N-oxide (TMAO), has been reported to be closely related to CKD complications. This study aimed to investigate the changes in intestinal microbiota and circulating levels of TMAO in Chinese patients with CKD. Methods The study comprised 50 paticipants including 30 patients with CKD and a control group of 20 healthy controls. Plasma TMAO levels were detected by high-performance liquid chromatography-tandem mass spectrometry, and gut microbiota was analysed using High-throughput sequencing. Results Compared to the healthy control group, the CKD patients had relatively lower albumin and hemoglobin levels and showed obviously impaired renal function and abnormal urine test results. Additionally, CKD patients showed increased plasma TMAO levels, especially those with a low glomerular filtration rate (GFR). Among the biochemical indices of the CKD patients, impaired renal function was the main contributor of the increased TMAO levels. High-throughput sequencing revealed obvious gut dysbiosis in CKD patients with biased community constitutions. Based on the Pearson correlation analysis, many bacteria positively or negatively correlated with TMAO production at the phylum and genus levels. Conclusions Our study demonstrated that gut microbiota dysbiosis and decreased GFR were the main causes of plasma TMAO level. Elevation, and inhibition of intestinal metabolite TMAO production may be the key to preventing CKD progression.Keywords
All Related Versions
This publication has 25 references indexed in Scilit:
- A comparative study of the gut microbiota in immune-mediated inflammatory diseases—does a common dysbiosis exist?Microbiome, 2018
- Altered gut microbiota and microbial biomarkers associated with chronic kidney diseaseMicrobiologyopen, 2018
- Microbiota issue in CKD: how promising are gut-targeted approaches?Journal Of Nephrology, 2018
- Exploring Bacteroidetes: Metabolic key points and immunological tricks of our gut commensalsDigestive and Liver Disease, 2018
- Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patientsScientific Reports, 2017
- Microbiome and metabolic disease: revisiting the bacterial phylum BacteroidetesJournal of Molecular Medicine, 2016
- Serum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic Kidney DiseasePLOS ONE, 2016
- The Role of the Gut Microbiome on Chronic Kidney Disease2016
- Gut Microbiota-Dependent Trimethylamine N -Oxide (TMAO) Pathway Contributes to Both Development of Renal Insufficiency and Mortality Risk in Chronic Kidney DiseaseCirculation Research, 2015
- Prevalence of chronic kidney disease in China: a cross-sectional surveyThe Lancet, 2012